Jaypirca (pirtobrutinib) — Medica
Mantle cell lymphoma
Initial criteria
- Patient is age ≥ 18 years
- Patient meets ONE of the following: has tried at least one systemic chemotherapy regimen OR is not a candidate for a chemotherapy regimen
- Patient has tried one Bruton tyrosine kinase (BTK) inhibitor for mantle cell lymphoma (e.g., Brukinsa, Calquence, or Imbruvica)
Approval duration
1 year